

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

MUTATIONAL ANALYSIS OF THE HUMAN FACTOR IX PROMOTER

**Jacqueline Elizabeth Manttan
1998**

A thesis presented in partial fulfilment of
the requirements for the degree of
Master of Science in Genetics
at Massey University.

Acknowledgments

I would like to thank my principal supervisor, Dr. Kathryn Stowell for the guidance, support and encouragement given throughout the years of my Masterate degree at Massey University.

Thank-you to the members of the 'Twilight Zone' for your all your help and friendship. I have had some great times within the lab (as well as the odd disaster) and have made some wonderful friends. Thank-you Robyn Marston and Carol Flyger for your technical advise and for providing plenty of laughs.

A big thanks to Bryce Cummock, Deb Knight, Andrew Norman and Shona Reilly for all their computer assistance - you guys were my 'knights in shining armour' when it came to computers!. Also I would like to thank Jason Wathne for the great curries cooked!.

I would like to thank my parents, Dayle and Bruce Manttan for all their love and support throughout my tertiary education. Thanks Dad for correcting my grammar (shocking as it was) and attempting to understand the science 'lingo' in order to do so!. I would also like to pay tribute to my sister Suzanne, who unfortunately cannot be here today. I know you would have been proud of me. This thesis is dedicated to you.

Last but not least, thank-you Dave for all the time, effort, guidance and support that you have given me throughout the course of my M.Sc. Now I can support you!.

Although haemophilia provides for an expansive area of research, I hope that this topic will not fall to the wayside of more politically favoured or "trendy" subjects as researchers struggle to attain funding.

Table of contents

Abstract	i
Abbreviations	iii
List of Figures	v
List of Tables	vii

CHAPTER ONE: INTRODUCTION..... 1

1.1 BACKGROUND TO HAEMOPHILIA B	1
1.2 HISTORICAL PERSPECTIVES OF HAEMOPHILIA B.....	1
1.3 FACTOR IX AND ITS INVOLVEMENT IN THE BLOOD COAGULATION CASCADE.....	2
1.4 THE FACTOR IX GENE	5
1.5 TRANSCRIPTIONAL REGULATION OF HUMAN FACTOR IX	6
1.6 THE RECOVERY OF HAEMOPHILIA B LEYDEN	9
1.7 GENERAL MECHANISMS OF TRANSCRIPTION.....	11
1.8 LIVER-SPECIFIC GENE EXPRESSION	11
1.9 THE EXPERIMENTAL AIMS OF THIS THESIS	13

CHAPTER 2. MATERIALS AND METHODS.....15

2.1 MATERIALS.....	15
2.2 METHODS	17
2.2.1 Introduction.....	17
2.2.1.1 <i>An overview of cell culture methodology</i>	17
2.2.2 Cell culture and transfection	18
2.2.2.1 <i>Recovery of cells from liquid nitrogen</i>	18
2.2.2.2 <i>Passaging of cells</i>	18
2.2.2.3 <i>Maintenance of frozen stocks</i>	19

2.2.2.4 Maintenance of cells	19
2.2.2.5 Transient transfections	19
2.2.2.6 Harvesting Cells	21
2.2.2.7 Addition of interleukin-6	21
2.2.2.9 β -galactosidase assay	22
2.2.3 Construction of the luciferase reporter vectors	22
2.2.3.1 An overview:	22
2.2.3.2 PCR amplification of the factor IX minimal promoter	24
2.2.3.3 Restriction digestion of PCR products	24
2.2.3.4 Restriction digestion of the vector	24
2.2.3.5 Removal of the 5' phosphate groups	25
2.2.3.6 Quantitation	25
2.2.3.7 Ligations and transformation	25
2.2.3.8 Rapid boil preparation and analysis	26
2.2.3.9 Glycerol stocks	26
2.2.4 DNA sequence analysis of the factor IX promoter	26
2.2.4.1 Preparation of templates for manual sequencing	26
2.2.4.2 Preparation of sequencing templates for automated sequencing	27
2.2.5 Large scale preparations of the factor IX clones	28
2.2.5.1 Wizard Maxiprep Preparation and Purification Method	28
2.2.5.2 Cesium chloride plasmid preparation	29
2.2.6 Electrophoretic mobility shift assay (EMSA)	29
2.2.6.1 Preparation of radioactive DNA probes for electrophoretic mobility shift assay	29
2.2.6.2 Electrophoretic mobility shift assays (EMSA)	30
2.2.6.3 Cos cell extract preparation	31

CHAPTER THREE: RESULTS 32

3.1 CELL CULTURE AND TRANSFECTION	32
3.1.1 Introduction	32
3.2 REPORTER GENE ASSAYS	33

3.2.1	Introduction.....	33
3.2.2	Assembly of the Reporter Gene Construct	35
3.2.2.1	<i>Preparation of the vector</i>	35
3.2.2.2	<i>Preparation of the factor IX promoter region</i>	37
3.3	POTENTIAL USE OF THE REPORTER GENE CONSTRUCTS	40
3.4	OPTIMISATION OF THE REPORTER GENE ASSAY SYSTEM	47
3.5	ANALYSIS OF THE -6 NUCLEOTIDE REGION.....	50
3.5.1	Introduction.....	50
3.5.2	Results.....	51
3.5.3	Discussion.....	54
3.6	A COMPARISON OF LUCIFERASE EXPRESSION FROM THE pGL2 BASIC AND pGL2 ENHANCER VECTORS	57
3.6.1	Introduction.....	57
3.6.2	Results.....	58
3.6.3	Discussion.....	60
3.7	THE ROLE OF HNF4 IN THE REGULATION OF FACTOR IX GENE EXPRESSION.....	61
3.7.1	Introduction.....	61
3.7.2	Results.....	62
3.7.3	Discussion.....	65
3.8	ANALYSIS OF PUTATIVE HNF4 BINDING SITES.	68
3.8.1	INTRODUCTION	68
3.8.2	Results.....	68
3.8.3	Discussion.....	71
3.9	THE ROLE OF THE CCAAT ENHANCER BINDING PROTEIN IN THE TRANSCRIPTION OF THE FACTOR IX PROMOTER.....	77
3.9.1	Introduction.....	77
3.9.2	Results.....	78
3.9.3	Discussion.....	80
3.11	FACTOR IX - AN ACUTE PHASE PROTEIN?.....	83
3.11.1	Introduction.....	83
3.11.2	Results.....	85

3.11.3 Discussion	88
3.12 ELECTROPHORETIC MOBILITY SHIFT ASSAYS	89
3.12.1 Introduction.....	89
3.12.2 Competition electrophoretic mobility shift assays.....	89
3.13 THE INTERACTION OF THE HNF4 TRANSCRIPTION FACTOR WITH THE FACTOR IX PROMOTER: AN EMSA STUDY.....	91
3.13.1 Introduction.....	91
3.13.2 Results.....	93
3.13.3 Discussion.....	95
 CHAPTER FOUR: FINAL DISCUSSION	96
4.1 INTRODUCTION.	96
4.2 FUTURE DIRECTIONS	98
4.2.1 Cultured cells: a feasible option?.....	98
4.3 RECOVERY OF HAEMOPHILIA B LEYDEN: THE POSSIBLE MECHANISMS MECHANISMS INVOLVED	100
4.4 RESEARCH INTO THE REGULATION OF THE FACTOR IX PROMOTER	103
 REFERENCES.....	104
APPENDIX 1.....	113
APPENDIX 2.....	114
APPENDIX 3.....	116
APPENDIX 4.....	117
APPENDIX 5.....	118

Abstract

Haemophilia B is a rare congenital bleeding disorder that affects 1 in 30,000 males. It is caused by a functional deficiency in the blood coagulation protein, factor IX, which is expressed primarily within the liver. Patients suffering from the Haemophilia B Leyden phenotype show a distinct pattern of factor IX expression that is characterised by severe to moderate haemophilia within children, which gradually ameliorates after puberty. Such deficiencies in factor IX are created by mutations that occur within the -22 to +13 region of the factor IX promoter. These mutations are responsible for down-regulating factor IX transcription leading to factor IX deficiency by disrupting the binding sites of transcription factors critical for factor IX gene expression. Three specific transcription factors, C/EBP, DBP and HNF4 are thought to be required for constitutive promoter expression.

The aim of this thesis was to analyse the roles of these three transcription factors in the regulation of the factor IX promoter. The current studies were focused on two regions (-220 to -202 and +20 to +45) of the factor IX promoter which have been implicated in transcriptional activation. Reporter gene assays using the human hepatoma cell line, Alexander, were carried out on both normal and mutant promoter constructs. Recognition sites for each of the three transcription factors were disrupted by oligonucleotide-directed PCR mutagenesis. The mutated promoter inserts were subsequently inserted into the luciferase reporter gene expression vector, pGL2 Basic (Promega). These constructs were then expressed within the Alexander cell line to compare the extent of transcriptional disruption created by each mutation. EMSA studies were also used to analyse the binding ability of the HNF4 transcription factor to the -6 region of the factor IX promoter.

Mutations within the -220 to +45 region of the factor IX promoter downregulated transcription from the promoter to different extents. This suggested that each transcription factor may play a different role in regulating the factor IX promoter. An increase in promoter expression observed with mutant constructs in the presence of exogenous HNF4 confirmed previous experiments which suggested that the HNF4

transcription factor could also act as an activator of promoter expression. Furthermore, the transactivation of the promoter constructs containing a mutation within the main HNF4 site at region -15 to -30 with exogenous HNF4, indicated that a second HNF4 site may be present within the factor IX promoter.

Abbreviations

A	adenine
AR	androgen receptor
ARE	androgen receptor element
bp	base pair
BRL	Bethesda research laboratories
C	cytosine
CAT	chloroamphenicol acetyl transferase
C/EBP	CCAAT enhancer binding protein
DBP	D-site binding protein
DMSO	dimethylsulphoxide
DNA	deoxyribonucleic acid
DNase I	deoxyribonuclease I
dNTP	deoxynucleotide triphosphate
DTT	dithiothreitol
<i>E.coli</i>	<i>Escherichia coli</i>
EDTA	ethylene diamine tetra-acetate
EMSA	electrophoretic mobility shift assay
G	guanine
HNF4	hepatocyte nuclear factor 4
IL-6	interleukin-6
kb	kilobase
kDa	kilodalton
ng	nanogram
MEM	minimal essential media
MPC	magnetic particle concentrator
mRNA	messenger ribonucleic acid
NF-1	nuclear factor 1
ONPG	o-Nitrophenol B-D-Galacto-pyranoside
PBS	phosphate buffered saline

PBSE	phosphate buffered saline EDTA
PCR	polymerase chain reaction
<i>Pfu</i>	<i>Pyrococcus furiosus</i>
PIC	pre-initiation complex
poly (dI-dC)	poly (dI-dC) poly (dI-dC)
RLU	relative light units
SDS	sodium dodecylsulphate
T	thymine
TAE	Tris acetate EDTA
Taq	<i>Thermus aquaticus</i>
TBE	Tris Boric acid EDTA
TEMED	N, N, N', N'-Tetramethylethylenediamine
TFIIA	transcription factor II A
TFIIB	transcription factor II B
TFIID	transcription factor II D
TFIIE	transcription factor II E
TFIIF	transcription factor II F
Tris	Tris-(hydroxymethyl) aminomethane
UV	ultraviolet
Xq27	chromosome X, long arm band 27

List of figures

Figure 1.	The blood clotting cascade	3
Figure 2.	The location of the factor IX gene on the X-chromosome at position Xq27.1.....	5
Figure 3.	Schematic representation of the human factor IX promoter.....	7
Figure 4.	The pre-initiation complex (PIC) formed on the promoter	12
Figure 5.	An outline of the procedures utilised in the preparation and maintenance of the hepatoma cell line, Alexander.....	17
Figure 6.	An outline of the procedures used for the preparation of reporter gene constructs.	23
Figure 7.	Digestion of the promoterless vector, pGL2 Basic with the restriction enzymes <i>Xho</i> 1 and <i>Sst</i> 1.....	36
Figure 8.	Amplification of the pTG3954 template by PCR mutagenesis	38
Figure 9.	Analysis of factor IX promoter inserts from the expression plasmid, pGL2 Basic.....	39
Figure 10.	A schematic representation of the mutations created within the human factor IX promoter.	43
Figure 11.	Optimisation of cell density in transient transfections	48
Figure 12.	Optimisation of cell density in transient transfections	49
Figure 13.	A comparison of the -6 G to A and -6 G to C promoter (region -220 to +45) mutations	53
Figure 14.	A comparison of luciferase expression between both normal and mutant promoter (region -220 to +45) constructs when present in either the promoterless pGL2 Basic or pGL2 Enhancer vector	59
Figure 15.	A comparison of the extent to which the normal and mutant (-6 G to C) promoter (region -220 to +45) constructs are transactivated in the presence of varying amounts of HNF4	64
Figure 16.	Analysis of the +20 to +45 region of the factor IX promoter	70
Figure 17.	A model for the interaction between the Androgen receptor and HNF4 binding sites.....	74

Figure 18.	A comparison of the extent to which the normal promoter (region -220 to +45) construct is transactivated in the presence and absence of the three C/EBP isoforms; C/EBP α , C/EBP β and C/EBP δ	79
Figure 19.	A schematic representation of the acute-phase response.....	84
Figure 20.	Transactivation of the factor IX promoter by the addition of IL-6	87
Figure 21.	Schematic diagram of the electrophoretic mobility shift assay (EMSA)....	90
Figure 22.	Determination of the protein concentration from the cellular extract.....	92
Figure 23.	Competitor EMSA using Cos 1-expressed HNF4.....	94

List of tables

Table 1. Oligonucleotides used for PCR mutagenesis.	40
Table 2. A summary of the reporter gene constructs that were prepared or utilised in these studies	46
Table 3. Luciferase activity in Alexander cells comparing normal and Leyden promoters	52
Table 4. Luciferase activity in Alexander cells comparing normal and Leyden promoters	58
Table 5. Luciferase activity in the Alexander cell line comparing both normal and mutant (-6 G to C) promoter constructs in the presence of varying amounts of HNF4.....	63
Table 6. Luciferase assay in Alexander cells comparing normal and Leyden promoters	69
Table 7. Levels of luciferase and β -galactosidase activity obtained from the first transfection within the Alexander cell line	86